SOHO 2022 | Promising treatment approaches for patients with MDS
David Sallman
• 3 Oct 2022
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into promising treatment approaches being investigated for patients with myelodysplastic syndromes (MDS), drawing focus on the role of magrolimab in this space. Dr Sallman shares some updates from a Phase Ib study evaluating the safety and efficacy of magrolimab plus azacitidine in patients with MDS, and further highlights the awaited results of the ongoing Phase III ENHANCE trial (NCT04313881). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
